News

Deal Announcements

Reata Pharma Closes $25 Million Series E Round

Monday, July 9, 2007 5:00:00 AM PDT | VentureDeal Staff
IRVING, TX -- Cancer drug company Reata Pharmaceuticals, Inc. announced that it has closed a fifth round of venture capital financing, receiving $25 million in new investment.

Reata is currently in clinical trials of its two lead cancer fighting candidates, RTA 402 and RTA 744.  RTA 402 is also in development for inflammatory diseases such as hepatitis and rheumatoid arthritis. 

Investors leading the round included CPMG, Inc. and Novo A/S.  The company intends to use the proceeds to fund Phase 2 studies of its lead candidates and continue development of its pre-clinical drugs.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1